Format

Send to

Choose Destination
Gynecol Oncol. 2017 Sep;146(3):603-608. doi: 10.1016/j.ygyno.2017.06.017. Epub 2017 Jun 29.

Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis.

Author information

1
Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand. Electronic address: npabalan@alumni.yorku.ca.
2
Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.
3
Department of Pathology, Phramongkutklao College of Medicine, Bangkok, Thailand.
4
Environmental Monitoring and Reporting Branch, Ontario Ministry of the Environment and Climate Change, 125 Resources Road, Toronto, Ontario, Canada.
5
Human Reproduction and Genetics Center, Department of Collective Health, Faculdade de Medicina do ABC, Santo André/SP, Brazil.

Abstract

BACKGROUND:

An epigenetic approach to explaining endometrial carcinogenesis necessitates good understanding of Ras association domain family 1 isoform A (RASSF1A) promoter methylation data from primary studies.

AIMS:

Differential magnitude of reported associations between RASSF1A promoter methylation and endometrial cancer (EC) prompted a meta-analysis to obtain more precise estimates.

METHODS:

Literature search yielded eight included articles. We calculated pooled odds ratios (OR) and 95% confidence intervals and subgrouped the data by race. Sources of heterogeneity were investigated with outlier analysis.

RESULTS:

The pooled ORs indicated increased risk, mostly significant. The overall effect (OR 11.46) was reflected in the European outcome (OR 15.07). However, both findings were heterogeneous (I2=57-70%) which when subjected to outlier treatment, erased heterogeneity (I2=0%) and retained significance (OR 9.85-12.66). Significance of these pre- and post-outlier outcomes were pegged at P≤0.0001. Only the Asian pre-outlier (OR 6.85) and heterogeneous (I2=82%) outcome was not significant (P=0.12) but when subjected to outlier treatment, erased heterogeneity (I2=0%) and generated significance (OR 23.74, P≤0.0001).

CONCLUSIONS:

Consistent increased risk associations underpinned by significance and robustness render RASSF1A with good biomarker potential for EC.

KEYWORDS:

Endometrial cancer; Meta-analysis; Methylation; RASSF1A; Ras association domain family 1 isoform A

PMID:
28669560
DOI:
10.1016/j.ygyno.2017.06.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center